Search results
Results from the WOW.Com Content Network
Croup (/ k r uː p / KROOP), also known as croupy cough, is a type of respiratory infection that is usually caused by a virus. [2] The infection leads to swelling inside the trachea, which interferes with normal breathing and produces the classic symptoms of "barking/brassy" cough, inspiratory stridor and a hoarse voice. [2]
Treatment typically takes place in hospital such as in a burn unit or intensive care unit. [3] [7] Efforts include stopping the cause, pain medication, and antihistamines. [3] [4] Antibiotics, intravenous immunoglobulins, and corticosteroids may also be used. [3] [4] Treatments do not typically change the course of the underlying disease. [3]
This is a list of drugs and substances that are known or suspected to cause Stevens–Johnson syndrome This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources .
Severe symptoms include coma and respiratory depression. Supportive care is the mainstay of treatment of benzodiazepine overdose. There is an antidote, flumazenil, but its use is controversial. [2] Deaths from single-drug benzodiazepine overdoses occur infrequently, [3] particularly after the point of hospital admission. [4]
TCA overdose may occur by accident or purposefully in an attempt to cause death. [2] The toxic dose depends on the specific TCA. [2] Most are non-toxic at less than 5 mg/kg except for desipramine, nortriptyline, and trimipramine, which are generally non-toxic at less than 2.5 mg/kg. [5] [2] In small children one or two pills can be fatal. [6]
According to his manager, Frey died from arthritis, colitis and pneumonia ? the latter two of which were caused by medications he was taking for the first. Glenn Frey's medication played a part in ...
Seventy-four percent were using Suboxone to ease withdrawal symptoms while sixty-four percent were using it because they couldn’t afford drug treatment. The researchers noted: “Common reasons given for not being currently enrolled in a buprenorphine/naloxone program included cost and unavailability of prescribing physicians.”
These side effects are serious and some of them are permanent, and many remain a crucial concern for companies and healthcare professionals and substantial efforts are being encouraged to reduce the potential risks for future antipsychotics through more clinical trials and drug development.